112 related articles for article (PubMed ID: 25280037)
1. An incomplete form of childhood Behçet's disease treated with infliximab.
Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
[TBL] [Abstract][Full Text] [Related]
2. Multiple cutaneous and mucocutaneous lesions as manifestations of pseudo-Behçet's disease.
Choudhary S; Srivastava A; Varadharajan A; Choudhary R
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37295812
[TBL] [Abstract][Full Text] [Related]
3. Behçet's disease.
Saadoun D; Wechsler B
Orphanet J Rare Dis; 2012 Apr; 7():20. PubMed ID: 22497990
[TBL] [Abstract][Full Text] [Related]
4. Effect of Infliximab on Chronic Progressive Neuro-Behçet's Disease: Influence of the Timing of Introduction on the Patient Outcome.
Hirohata S; Kikuchi H; Sawada T; Kuwana M; Kawachi I; Kirino Y; Ishigatsubo Y; Takeno M
Intern Med; 2024 Feb; 63(4):481-486. PubMed ID: 37344428
[TBL] [Abstract][Full Text] [Related]
5. Should we aim to define a stage of "pre" Behcet's syndrome?
Daood R; Hassan F; Naffaa ME
Int J Rheum Dis; 2024 May; 27(5):e15197. PubMed ID: 38769928
[No Abstract] [Full Text] [Related]
6. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Hayashi M; Tsuboi S; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Yoshioka Y; Ishiguro N
Rheumatology (Oxford); 2015 May; 54(5):854-9. PubMed ID: 25339638
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.
Rao VU; Pavlov A; Klearman M; Musselman D; Giles JT; Bathon JM; Sattar N; Lee JS
Arthritis Rheumatol; 2015 Feb; 67(2):372-80. PubMed ID: 25332171
[TBL] [Abstract][Full Text] [Related]
8. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.
Dai C; Liu WX; Jiang M; Sun MJ
PLoS One; 2014; 9(10):e110797. PubMed ID: 25330148
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept.
Ospina FE; Agualimpia A; Bonilla-Abadía F; Cañas CA; Tobón GJ
Case Rep Rheumatol; 2014; 2014():835050. PubMed ID: 25313341
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab therapy in children with Crohn disease previously treated with infliximab.
Cozijnsen M; Duif V; Kokke F; Kindermann A; van Rheenen P; de Meij T; Schaart M; Damen G; Norbruis O; Pelleboer R; Van den Neucker A; van Wering H; Hummel T; Oudshoorn J; Escher J; de Ridder L;
J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):205-10. PubMed ID: 25286063
[TBL] [Abstract][Full Text] [Related]
11. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?
Herfarth HH; Rogler G; Higgins PD
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):336-8. PubMed ID: 25285408
[No Abstract] [Full Text] [Related]
12. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
15. Managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers: similarities and differences.
Tursi A
Inflamm Bowel Dis; 2014 Dec; 20(12):E24-5. PubMed ID: 25374289
[No Abstract] [Full Text] [Related]
16. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
[TBL] [Abstract][Full Text] [Related]
17. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
Willrich MA; Murray DL; Snyder MR
Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
[TBL] [Abstract][Full Text] [Related]
20. Pustular psoriasis occurring after total colectomy for ulcerative colitis and relieved by administration of infliximab.
Saito K; Ito A; Ishikawa K; Shimada H; Takeo N; Hatano Y; Sugiura K; Akiyama M; Inomata M; Kitano S; Fujiwara S
J Dermatol; 2014 Nov; 41(11):1033-4. PubMed ID: 25297877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
